In Q1 2025, Gossamer Bio reported $9.9 million in collaboration revenue and a net loss of $36.6 million, while continuing to advance its registrational studies for seralutinib. The company closed new patient screening for its Phase 3 PROSERA Study and maintains a strong cash position to fund operations into the first half of 2027.

Gossamer Bio announced a net loss of $33.0 million for Q4 2024, an improvement from the $48.1 million net loss in Q4 2023. The company's total revenue for the quarter was $9.379 million, and it ended the year with $294.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the first half of 2027.

Gossamer Bio reported $327 million in cash, cash equivalents and marketable securities as of September 30, 2024. Revenue from contracts with collaborators was $9.5 million. R&D expenses were $34.9 million, and G&A expenses were $8.5 million. The net loss for the quarter was $30.8 million, or $0.14 per share.

Gossamer Bio reported a net income of $49.2 million for the second quarter of 2024, with $354.5 million in cash, cash equivalents, and marketable securities as of June 30, 2024. Revenue from the sale of licenses was $88.8 million and revenue from contracts with collaborators was $7.1 million.

Gossamer Bio announced its Q1 2024 financial results, highlighting a collaboration with Chiesi, ongoing Phase 3 study in PAH, and advancement of Seralutinib. The company reported a net loss of $41.9 million, with $396 million in cash, cash equivalents, and marketable securities pro forma.

Gossamer Bio reported a net loss of $48.1 million for the quarter ended December 31, 2023, with cash, cash equivalents, and marketable securities totaling $296.4 million at year-end. The first PAH patient was dosed in the Phase 3 PROSERA study, and Japan was included in the study following CTN acceptance by PMDA.

Gossamer Bio announced its Q3 2023 financial results, highlighting the progress of the seralutinib Phase 3 PROSERA Study and the presentation of data from the Phase 2 TORREY lung imaging sub-study. The company reported cash, cash equivalents, and marketable securities of $328.9 million as of September 30, 2023, which are expected to fund operations into the first half of 2026.

Gossamer Bio reported a net loss of $42.5 million for the second quarter ended June 30, 2023. The company's cash, cash equivalents, and marketable securities totaled $162.1 million as of June 30, 2023, which, combined with proceeds from a July private placement, is expected to fund operations into the first half of 2026.

Gossamer Bio announced its Q1 2023 financial results, reporting a net loss of $49.2 million, or $0.52 per share. The company had $201.9 million in cash, cash equivalents, and marketable securities as of March 31, 2023. They are focusing on the development of seralutinib for PAH treatment and expect to initiate a Phase 3 clinical trial in Q3 2023.

Gossamer Bio reported its Q4 2022 financial results, with a net loss of $55.8 million, or $0.59 per share. The company's cash, cash equivalents, and marketable securities totaled $255.7 million as of December 31, 2022.

Gossamer Bio reported a net loss of $59.4 million for the third quarter ended September 30, 2022, with $304.4 million in cash, cash equivalents, and marketable securities as of the same date. The company's Phase 2 TORREY Study of seralutinib is on track for topline readout in the second half of November or first half of December.

Gossamer Bio reported a net loss of $56.5 million for the second quarter of 2022, with cash, cash equivalents, and marketable securities totaling $222.2 million as of June 30, 2022.

Gossamer Bio reported a net loss of $57.8 million for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $271.6 million as of March 31, 2022. Enrollment has completed in the ongoing TORREY Study, a Phase 2 clinical trial in patients with PAH.

Gossamer Bio reported a net loss of $56.3 million for the fourth quarter of 2021, with cash, cash equivalents, and marketable securities totaling $325.2 million at year-end. The company anticipates these funds, along with access to a debt facility, will sufficiently cover operating and capital expenditures into the second half of 2023. They are also anticipating topline results for their Phase 2 SHIFT-UC and TORREY studies in the second quarter and second half of 2022, respectively.

Gossamer Bio reported a net loss of $60.2 million for the third quarter of 2021, with cash, cash equivalents, and marketable securities totaling $366 million as of September 30, 2021.

Gossamer Bio reported cash, cash equivalents and marketable securities totaling $406 million as of June 30, 2021. The company's net loss for the quarter ended June 30, 2021, was $59.8 million, or $0.80 per share.

Gossamer Bio reported a net loss of $57.6 million, or $0.78 per share, for the quarter ended March 31, 2021. Cash, cash equivalents and marketable securities totaled $453.3 million as of March 31, 2021.

Gossamer Bio reported a net loss of $57.8 million for the third quarter of 2020. As of September 30, 2020, the company's cash, cash equivalents, and marketable securities totaled $555.4 million.

Gossamer Bio reported a net loss of $66.9 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $600.4 million as of June 30, 2020, which is expected to fund operations into 2024.

Gossamer Bio announced the completion of the interim analysis of the LEDA study of GB001 and topline results from the Phase 1b study of GB004 in patients with active mild-to-moderate ulcerative colitis. Cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020.

Gossamer Bio reported cash, cash equivalents and marketable securities of $401.8 million as of December 31, 2019. R&D expenses for the quarter ended December 31, 2019 were $42.6 million, and the net loss for the three months ended December 31, 2019, was $54.7 million, or $0.89 per share.